The Scottish Medicines Consortium approves Cimzia (certolizumab pegol) for the treatment of psoriasis.
The Scottish Medicines Consortium (SMC) has today published its acceptance of Cimzia (certolizumab pegol) as a treatment for psoriasis in Scotland.
Cimzia may be prescribed for the treatment of moderate to severe plaque psoriasis in adult patients who have not responded to standard systemic therapies (including ciclospin, methotrexate and phototherapy), or who cannot take these medications.
Cimzia is a biologic treatment which is taken by an injection every 2 weeks (after the 'loading dose' of two injections in each of weeks 0,2 and 4). It blocks tumour necrosis factor-alpha (TNF alpha) a chemical ‘messenger’ in the immune system that signals other cells to cause inflammation.
There is too much TNF alpha in the skin of people with psoriasis, which causes inflammation and can lead to tissue damage. TNF alpha can also lead to increased activity of the immune system by switching on certain white blood cells in the body, called T Cells. Once T cells become overactive they can trigger inflammation and other immune responses, encouraging the development of psoriasis.
Cimzia helps lower the amount of TNF alpha to more normal levels, and switches off the inflammatory cycle of psoriasis. This leads to improvement in symptoms for many people who take it.
We will be publishing more information on Cimzia for psoriasis soon. In the meantime, please get in touch with us if you have any questions.